Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Travere Therapeutics (NASDAQ: TVTX) is set to release its first quarter 2023 financial results on May 4, 2023, following the close of U.S. markets. The company will hold a conference call and webcast at 4:30 p.m. ET to discuss the results and provide updates on its business. Interested parties can access the information on the Investor page of Travere’s website. Travere Therapeutics focuses on developing therapies for rare diseases, emphasizing its commitment to supporting patients and families facing these challenges. This upcoming earnings release may provide insights into the company’s financial health and strategic direction, crucial for stakeholders and investors.
Travere Therapeutics has announced the grant of inducement equity awards to five new employees, with a total of 30,000 restricted stock units (RSUs) issued on April 10, 2023. These RSUs, which are part of the 2018 Equity Incentive Plan, are specifically intended to attract new talent in accordance with Nasdaq Listing Rule 5635(c)(4). The vesting schedule for these RSUs spans four years, with 25% vesting on each anniversary, contingent upon the employees maintaining their service with the company.
Travere Therapeutics is dedicated to developing therapies for rare diseases, focusing on patient needs and community involvement to improve treatment outcomes.
Travere Therapeutics (TVTX) announced significant findings from the interim analysis of the Phase 3 PROTECT Study for FILSPARI™ (sparsentan), published in The Lancet. The data showed a mean reduction in proteinuria of 49.8% after 36 weeks of treatment with FILSPARI, contrasting sharply with a 15.1% reduction for irbesartan (p0.0001). Moreover, 20.8% of patients on FILSPARI achieved complete remission, versus 7.9% for irbesartan (p=0.0005). The results indicate FILSPARI's potential for long-term benefits on kidney function and confirm its favorable safety profile, with adverse events comparable to irbesartan. Topline results for the study's confirmatory analysis are expected in Q4 2023.